ArticleKidney research and clinical practice2026
Genetic diagnosis of hereditary kidney disease in pediatric patients through whole-exome sequencing and mitochondrial DNA analysis.
Article in Kidney research and clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Response to the letter regarding "Genetic diagnosis of hereditary kidney disease in pediatric patients through whole-exome sequencing and mitochondrial DNA analysis".Kidney research and clinical practice · 2026Article
- Before new variants in genes associated with hematuria or proteinuria can be classified as causative, their pathogenicity must be demonstrated.Kidney research and clinical practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIdentifying the genetic cause of hereditary kidney disease is essential for appropriate management. However, pediatric patients often present with nonspecific renal symptoms such as proteinuria, hematuria, or both, making accurate diagnosis difficult. Mitochondrial diseases are also an important but underrecognized etiology of hereditary kidney disorders. This study aimed to assess the diagnostic utility of whole-exome sequencing (WES) combined with mitochondrial DNA (mtDNA) analysis and to describe the clinical and genetic features of pediatric patients presenting with isolated proteinuria, combined hematuria and proteinuria, or hematuria with a relevant family history.
methodsDNA was extracted from peripheral blood leukocytes of 77 pediatric patients with hematuria and/or proteinuria with or without family history. WES and mtDNA analyses were conducted to identify underlying genetic etiologies.
resultsThe overall molecular diagnostic yield was 54.5% (42/77) with COL4A-related nephropathy (29 cases) being the most prevalent diagnosis. Notably, one patient with no systemic symptoms except for renal manifestations was identified with the m.3243A>G variant in MT-TL1, which is associated with the MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) syndrome. This patient's initial and predominant presentation was gross and microscopic hematuria, diverging from typical MELAS-associated kidney disease.
conclusionWES proved valuable in diagnosing hereditary kidney diseases in pediatric patients with nonspecific urinalysis findings. Incorporating mtDNA analysis further improved diagnostic yield and enabled identification of atypical presentations of mitochondrial disorders, such as MELAS, even when renal symptoms were isolated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.